NASDAQ:ATRA Atara Biotherapeutics - ATRA Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Atara Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $5.41 +0.24 (+4.64%) (As of 02/6/2023 04:09 PM ET) Add Compare Share Share Today's Range$5.11▼$5.6450-Day Range$2.85▼$5.4652-Week Range$2.83▼$16.07Volume751,870 shsAverage Volume1.05 million shsMarket Capitalization$513.30 millionP/E RatioN/ADividend YieldN/APrice Target$21.63 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Atara Biotherapeutics MarketRank™ ForecastAnalyst RatingHold2.14 Rating ScoreUpside/Downside265.2% Upside$19.50 Price TargetShort InterestBearish14.37% of Shares Sold ShortDividend StrengthN/ASustainability-0.87Upright™ Environmental ScoreNews Sentiment1.05Based on 2 Articles This WeekInsider TradingSelling Shares$133,802 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.05) to ($2.44) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.86 out of 5 starsMedical Sector739th out of 1,027 stocksBiological Products, Except Diagnostic Industry122nd out of 169 stocks 3.1 Analyst's Opinion Consensus RatingAtara Biotherapeutics has received a consensus rating of Hold. The company's average rating score is 2.14, and is based on 3 buy ratings, 2 hold ratings, and 2 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $19.50, Atara Biotherapeutics has a forecasted upside of 265.2% from its current price of $5.34.Amount of Analyst CoverageAtara Biotherapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted14.37% of the outstanding shares of Atara Biotherapeutics have been sold short.Short Interest Ratio / Days to CoverAtara Biotherapeutics has a short interest ratio ("days to cover") of 9.5.Change versus previous monthShort interest in Atara Biotherapeutics has recently increased by 4.77%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAtara Biotherapeutics does not currently pay a dividend.Dividend GrowthAtara Biotherapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAtara Biotherapeutics has received a 75.69% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer", "Clinical research services for physiological diseases ", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Atara Biotherapeutics is -0.87. Previous Next 2.8 News and Social Media Coverage News SentimentAtara Biotherapeutics has a news sentiment score of 1.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Atara Biotherapeutics this week, compared to 2 articles on an average week.Search Interest24 people have searched for ATRA on MarketBeat in the last 30 days. This is an increase of 4% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Atara Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Atara Biotherapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $133,802.00 in company stock.Percentage Held by InsidersOnly 4.00% of the stock of Atara Biotherapeutics is held by insiders. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Atara Biotherapeutics are expected to decrease in the coming year, from ($2.05) to ($2.44) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Atara Biotherapeutics is -2.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Atara Biotherapeutics is -2.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAtara Biotherapeutics has a P/B Ratio of 1.69. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Atara Biotherapeutics (NASDAQ:ATRA) StockAtara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.Read More Receive ATRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Atara Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ATRA Stock News HeadlinesFebruary 6, 2023 | finance.yahoo.comAtara Biotherapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results on Wednesday, February 8, 2023January 28, 2023 | americanbankingnews.comBrokerages Set Atara Biotherapeutics, Inc. (NASDAQ:ATRA) PT at $19.50February 6, 2023 | Investing Trends (Ad)Profit From the Commercial Solar Boom?Solar energy had its best year ever in 2021, with a record 24 gigawatts of power installed. That's enough to power 18 million homes! Analysts expect the global solar farm market to reach $356 billion by 2028. The utility segment of the solar market is expected to grow at the highest annual growth rate in the industry, especially with the many tax incentives now offered. January 4, 2023 | finance.yahoo.comAtara Biotherapeutics to Present at the 41st Annual J.P. Morgan Healthcare ConferenceJanuary 4, 2023 | finance.yahoo.comAtara Biotherapeutics to Present at the 41st Annual J.P. Morgan Healthcare ConferenceDecember 20, 2022 | marketwatch.comAtara Biotherapeutics Gets $31M Royalty Interest Financing Deal, Shares Rise 6%December 20, 2022 | finance.yahoo.comAtara Biotherapeutics Announces $31 Million Royalty Interest Financing Agreement with HealthCare RoyaltyDecember 19, 2022 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Staar Surgical (STAA), Madrigal Pharmaceuticals (MDGL) and Atara Biotherapeutics (ATRA)February 6, 2023 | Investing Trends (Ad)Profit From the Commercial Solar Boom?Solar energy had its best year ever in 2021, with a record 24 gigawatts of power installed. That's enough to power 18 million homes! Analysts expect the global solar farm market to reach $356 billion by 2028. The utility segment of the solar market is expected to grow at the highest annual growth rate in the industry, especially with the many tax incentives now offered. December 19, 2022 | benzinga.comAtara Biotherapeutics' Ebvallo™ (tabelecleucel) Receives European Commission Approval as First Ever Therapy for Adults and Children with EBV+ PTLDDecember 19, 2022 | markets.businessinsider.comAtara's Ebvallo Receives European Commission Approval For Adults And Children With EBV+ PTLDDecember 19, 2022 | finance.yahoo.comAtara Biotherapeutics’ Ebvallo™ (tabelecleucel) Receives European Commission Approval as First Ever Therapy for Adults and Children with EBV+ PTLDDecember 19, 2022 | finance.yahoo.comAtara Biotherapeutics Announces Changes to Its Board of DirectorsDecember 17, 2022 | seekingalpha.comConsider Atara Biotherapeutics As The Tab-Cel Delay Resolves In The U.S.December 12, 2022 | finance.yahoo.comAtara Biotherapeutics Presents Updated Clinical Data from Pivotal Phase 3 Trial (ALLELE) of Tab-cel® at the 64th American Society of Hematology (ASH) Annual MeetingNovember 23, 2022 | finance.yahoo.comAtara Biotherapeutics to Participate at the Evercore ISI 5th Annual HealthCONx ConferenceNovember 22, 2022 | finance.yahoo.comNewsflash: Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Analysts Have Been Trimming Their Revenue ForecastsNovember 10, 2022 | finance.yahoo.comAtara Biotherapeutics Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS In LineNovember 9, 2022 | finance.yahoo.comAtara Biotherapeutics to Participate at the Stifel Healthcare ConferenceNovember 8, 2022 | markets.businessinsider.comMizuho Securities Keeps Their Buy Rating on Atara Biotherapeutics (ATRA)November 8, 2022 | finance.yahoo.comAtara Biotherapeutics Announces Third Quarter 2022 Financial Results and Operational ProgressNovember 7, 2022 | msn.comAtara Biotherapeutics's Earnings: A PreviewNovember 1, 2022 | finance.yahoo.comAtara Biotherapeutics to Announce Third Quarter 2022 Financial Results on Tuesday, November 8, 2022October 26, 2022 | finance.yahoo.comAtara Biotherapeutics Presents New MRI and Updated Open-Label Extension Data from Phase 1 Study of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2022October 14, 2022 | finance.yahoo.comCHMP Recommends Approval of Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative DiseaseOctober 10, 2022 | finance.yahoo.comAtara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)October 7, 2022 | finance.yahoo.comAllogene (ALLO) Begins Phase II Study on Allogeneic CAR T TherapySee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ATRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Atara Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ATRA Company Calendar Last Earnings11/08/2022Today2/06/2023Next Earnings (Estimated)2/27/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ATRA CUSIPN/A CIK1604464 Webwww.atarabio.com Phone(650) 278-8930FaxN/AEmployees578Year FoundedN/APrice Target and Rating Average Stock Price Forecast$19.50 High Stock Price Forecast$50.00 Low Stock Price Forecast$3.00 Forecasted Upside/Downside+299.7%Consensus RatingHold Rating Score (0-4)2.14 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-340,140,000.00 Net Margins-348.49% Pretax Margin-348.43% Return on Equity-125.38% Return on Assets-71.22% Debt Debt-to-Equity RatioN/A Current Ratio3.92 Quick Ratio3.92 Sales & Book Value Annual Sales$20.34 million Price / Sales25.24 Cash FlowN/A Price / Cash FlowN/A Book Value$3.16 per share Price / Book1.71Miscellaneous Outstanding Shares94,880,000Free Float91,084,000Market Cap$513.30 million OptionableOptionable Beta0.94 Key ExecutivesPascal TouchonPresident, Chief Executive Officer & DirectorUtpal KoppikarChief Financial Officer & Senior Vice PresidentManher AJ JoshiChief Medical OfficerJakob DupontGlobal Head-Research & DevelopmentAnhco NguyenChief Scientific OfficerKey CompetitorsCompass TherapeuticsNASDAQ:CMPXCaribou BiosciencesNASDAQ:CRBUSorrento TherapeuticsNASDAQ:SRNECullinan OncologyNASDAQ:CGEMbluebird bioNASDAQ:BLUEView All CompetitorsInsiders & InstitutionsSG Americas Securities LLCSold 4,878 shares on 2/2/2023Ownership: 0.028%Pinnacle Associates Ltd.Sold 5,216 shares on 2/1/2023Ownership: 0.414%Zurcher Kantonalbank Zurich Cantonalbank Bought 2,909 shares on 2/1/2023Ownership: 0.014%Pinnacle Associates Ltd.Bought 20,459 shares on 1/25/2023Ownership: 0.441%Allspring Global Investments Holdings LLCBought 7,529 shares on 1/23/2023Ownership: 0.048%View All Insider TransactionsView All Institutional Transactions ATRA Stock - Frequently Asked Questions Should I buy or sell Atara Biotherapeutics stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Atara Biotherapeutics in the last year. There are currently 2 sell ratings, 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ATRA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ATRA, but not buy additional shares or sell existing shares. View ATRA analyst ratings or view top-rated stocks. What is Atara Biotherapeutics' stock price forecast for 2023? 7 equities research analysts have issued 12-month price objectives for Atara Biotherapeutics' shares. Their ATRA share price forecasts range from $3.00 to $50.00. On average, they expect the company's stock price to reach $19.50 in the next twelve months. This suggests a possible upside of 253.9% from the stock's current price. View analysts price targets for ATRA or view top-rated stocks among Wall Street analysts. How have ATRA shares performed in 2023? Atara Biotherapeutics' stock was trading at $3.28 on January 1st, 2023. Since then, ATRA shares have increased by 68.0% and is now trading at $5.51. View the best growth stocks for 2023 here. When is Atara Biotherapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023. View our ATRA earnings forecast. How were Atara Biotherapeutics' earnings last quarter? Atara Biotherapeutics, Inc. (NASDAQ:ATRA) released its quarterly earnings results on Tuesday, November, 8th. The biotechnology company reported ($0.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.78) by $0.04. The biotechnology company had revenue of $4.46 million for the quarter, compared to analyst estimates of $4.37 million. Atara Biotherapeutics had a negative trailing twelve-month return on equity of 125.38% and a negative net margin of 348.49%. What is Pascal Touchon's approval rating as Atara Biotherapeutics' CEO? 38 employees have rated Atara Biotherapeutics Chief Executive Officer Pascal Touchon on Glassdoor.com. Pascal Touchon has an approval rating of 60% among the company's employees. This puts Pascal Touchon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 88.0% of employees surveyed would recommend working at Atara Biotherapeutics to a friend. What other stocks do shareholders of Atara Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Atara Biotherapeutics investors own include CRISPR Therapeutics (CRSP), AbbVie (ABBV), Exelixis (EXEL), Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), OPKO Health (OPK), Gilead Sciences (GILD), Micron Technology (MU) and Pfizer (PFE). What is Atara Biotherapeutics' stock symbol? Atara Biotherapeutics trades on the NASDAQ under the ticker symbol "ATRA." Who are Atara Biotherapeutics' major shareholders? Atara Biotherapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Pinnacle Associates Ltd. (0.44%), Pinnacle Associates Ltd. (0.41%), Hennion & Walsh Asset Management Inc. (0.29%), Allspring Global Investments Holdings LLC (0.05%), SG Americas Securities LLC (0.03%) and Zurcher Kantonalbank Zurich Cantonalbank (0.01%). Insiders that own company stock include Amar Murugan, Jakob Dupont, Joe Newell, Kristin Yarema, Matthew K Fust, Pascal Touchon, Thomas Peterffy and Utpal Koppikar. View institutional ownership trends. How do I buy shares of Atara Biotherapeutics? Shares of ATRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Atara Biotherapeutics' stock price today? One share of ATRA stock can currently be purchased for approximately $5.51. How much money does Atara Biotherapeutics make? Atara Biotherapeutics (NASDAQ:ATRA) has a market capitalization of $522.79 million and generates $20.34 million in revenue each year. The biotechnology company earns $-340,140,000.00 in net income (profit) each year or ($2.47) on an earnings per share basis. How many employees does Atara Biotherapeutics have? The company employs 578 workers across the globe. How can I contact Atara Biotherapeutics? Atara Biotherapeutics' mailing address is 611 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.atarabio.com. The biotechnology company can be reached via phone at (650) 278-8930 or via email at ehyllengren@atarabio.com. This page (NASDAQ:ATRA) was last updated on 2/6/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.